Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial
Esophageal Neoplasm
About this trial
This is an interventional supportive care trial for Esophageal Neoplasm focused on measuring intraoperative, fluid management, esophageal carcinoma, surgery, gas exchange, tissue perfusion
Eligibility Criteria
Inclusion Criteria:
- esophageal carcinoma
- Lewis Tanner procedure (median laparotomy and right thoracotomy)
Exclusion Criteria:
- younger than 18 years
- severe lung disease
- chronic renal insufficiency
- a physical status classification > III on the American Society of Anesthesiologists (ASA) scale
- impossible to perform epidural catheter placement
- thoraco-phreno-laparotomy
Sites / Locations
- Department of Thoracic surgery "Jordanovac" University Hospital Centre Zagreb
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Restrictive group
Liberal group
Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Patients who received > 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.